# This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile.

> **NCT06756451** · PHASE1 · RECRUITING · sponsor: **Nanjing RegeneCore Biotech Co., Ltd.** · enrollment: 71 (estimated)

## Conditions studied

- Hematologic Malignancies

## Interventions

- **DRUG:** RJK-RT2831 dose-escalation phase Ia
- **DRUG:** RJK-RT2831 Dose Expansion Phase Ib

## Key facts

- **NCT ID:** NCT06756451
- **Lead sponsor:** Nanjing RegeneCore Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-25
- **Primary completion:** 2028-04-08
- **Final completion:** 2028-07-14
- **Target enrollment:** 71 (ESTIMATED)
- **Last updated:** 2026-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06756451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06756451, "This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06756451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*